Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

Interventions

  • DRUG Current standard of care treatment options

Study Locations (20)

Florida

  • Local Institution - 0063 — Fort Lauderdale
  • Local Institution - 0061 — Hollywood
  • LIFE Clinical Trials — Margate
  • Local Institution - 0068 — Palm Beach Gardens

California

  • Local Institution - 0054 — La Jolla
  • Local Institution - 0001 — La Palma
  • Rheumatology Center of San Diego — San Diego

Michigan

  • Local Institution - 0034 — Ann Arbor
  • AA MRC — Grand Blanc

North Carolina

  • DJL Clinical Research, PLLC — Charlotte
  • Local Institution - 0037 — Durham

Arizona

  • Local Institution - 0062 — Mesa

Illinois

  • Local Institution - 0065 — Willowbrook

Maryland

  • Local Institution - 0064 — Rockville

New Jersey

  • Local Institution - 0060 — West Long Branch

Trial Details

FieldValue
Enrollment Target 223 participants
Start Date 2025-10-08
Est. Completion 2032-11-01

Sponsor

Bristol-Myers Squibb

504 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07175285

The ClinicalTrials.gov registry entry for NCT07175285 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 504 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention — of which Current standard of care treatment options is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07175285 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Florida, California, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07175285 about?

NCT07175285 is a clinical study titled "A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants". The purpose of this study is to characterize the efficacy and safety of current standard of care treatment options in participants with active systemic lupus erythematosus (SLE; including lupus nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants

What is the current status of trial NCT07175285?

This trial is currently recruiting. The enrollment target is 223 participants. The study started on 2025-10-08. Estimated completion is 2032-11-01.

What conditions does trial NCT07175285 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07175285?

The interventions under investigation include: Current standard of care treatment options (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07175285?

This trial is sponsored by Bristol-Myers Squibb, which has 504 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07175285 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial